Search Results - "Mauriño, P. Sanchez"

432P Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor by Berlanga, L. Navarro, Teso, B., Paco, P. Flores, De la Haba Rodriguez, J., Armenta, A., Mora, F., Alonso, B. Rodriguez, Estevez, C. Morales, Quintela, I. Porras, Mauriño, P. Sanchez, Aguilar, E. Aranda

Get full text

1114P Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE) by Soria, A., Sanchez Mauriño, P., García Galindo, R., Sequero, S., Gutiérrez Sanz, L., Crespo, G., Díaz-Beveridge, R., Puértolas, T., López, P., Fra Rodríguez, J., López Castro, R., Aguayo, C., Valdivia, J., Cunquero-Tomás, A., Benítez, G., Ayala de Miguel, P., Espinosa, E., Muñoz-Couselo, E., Campos, B., Cerezuela-Fuentes, P.

Get full text

826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial by Marquez-Rodas, I., Arance Fernandez, A.M., Berciano Guerrero, M.A., Garcia Castano, A., Alamo De La Gala, M.D.C., Gonzalez Cao, M., Sanchez Mauriño, P., Diaz Beveridge, R.P., Valduvieco, I., Delgado, R., Prada, P.J., Puertas, E., Romero, J.L., Conde, A., Alvarez, A., Berrocal, A.

Get full text

PO-1557 RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II by Alvarez, A., Valduvieco, I., Arance, A., Delgado, R., Berciano, M.A., López Campos, F., Soria, A., Romero, J.L., Sánchez Mauriño, P., Lucas, A., Martín Liberal, J., Prada, P.J., García Castaño, A., Alamo, M.C., Puertas, E., González Cao, M., Conde, A., Díaz Beveridge, R., Corona, J.A., Aguado, C., Foro, P., Vidal, J., López Soler, F., Cerezuela Fuentes, P., Márquez Rodas, I.

Get full text

837P Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE) by Soria, A., Sánchez Mauriño, P., Serrano, J.J., Sequero, S., Fra Rodríguez, J., Amezcua, V., Benítez, G., Espinosa, E., Aguayo, C., García Galindo, R., Díaz-Beveridge, R., Puértolas, T., Cunquero-Tomás, A., López Castro, R., Crespo, G., López, P., Gutiérrez Sanz, L., Campos, B., García, L., Cerezuela-Fuentes, P.

Get full text

1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial by Marquez-Rodas, I., Arance, A., Berciano Guerrero, M.A., Díaz Beveridge, R., Alamo, M.D.C., Garcia Castaño, A., Gonzalez Cao, M., Vidal, J., Puertolas Hernandez, T., Soria, A., Aguado de la Rosa, C., Sánchez Mauriño, P., Valduvieco, I., Delgado Rico, R., Conde, A., Foro, P., Prada, P.J., Puertas, E., Alvarez Gonzalez, A., Berrocal, A.

Get full text

1868P Efficacy and safety of naloxegol in patients with cancer with opioid-induced constipation with laxative-inadequate response: A long-term, real-world study by Beato Zambrano, C., Cobo Dols, M., Cabezón Gutiérrez, L., Chicas-Sett, R., Blancas López-Barajas, M.I., García-Navalón, F.J., Firvida Pérez, J.L., Llorens Torromé, S., Togores Torres, P., Delgado Mingorance, I., Giraldo Marín, A., Librán Oriol, A., Paredes Lario, A., Sánchez Mauriño, P., Higuera Gómez, O., Moreno Muñoz, D., Huerta González, I., Sanz Yagüe, A., Soler López, B.

Get full text

1821P - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response by Cobo Dols, M., Beato Zambrano, M.D.C., Cabezón Gutiérrez, L., Chicas Sett, R., Blancas, I., García Navalón, F.J., Firvida Pérez, J.L., Serrano Bermúdez, G., Togores Torres, P., Delgado Mingorance, I., Giraldo Marín, A., Librán Oriol, A., Paredes Lario, A., Sánchez Mauriño, P., Higuera Gomez, O., Moreno Muñoz, D., Jiménez López, A.J., Huerta González, I., Sanz Yagüe, A., Soler López, B.

“…Naloxegol is a peripherally acting, µ-opioid receptor antagonist for treatment of opioid-induced constipation (OIC). The main objective of this study was to…”
Get full text

1821PAnalysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response by Cobo Dols, M, Beato Zambrano, M D C, Cabezón Gutiérrez, L, Chicas Sett, R, Blancas, I, García Navalón, F J, Firvida Pérez, J L, Serrano Bermúdez, G, Togores Torres, P, Delgado Mingorance, I, Giraldo Marín, A, Librán Oriol, A, Paredes Lario, A, Sánchez Mauriño, P, Higuera Gomez, O, Moreno Muñoz, D, Jiménez López, A J, Huerta González, I, Sanz Yagüe, A, Soler López, B

“…Abstract Background Naloxegol is a peripherally acting, µ-opioid receptor antagonist for treatment of opioid-induced constipation (OIC). The main objective of…”
Get full text

Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response by Cobo Dols, M., Beato Zambrano, M.D.C., Cabezón Gutiérrez, L., Chicas Sett, R., Blancas, I., García Navalón, F.J., Firvida Pérez, J.L., Serrano Bermúdez, G., Togores Torres, P., Delgado Mingorance, I., Giraldo Marín, A., Librán Oriol, A., Paredes Lario, A., Sánchez Mauriño, P., Higuera Gomez, O., Moreno Muñoz, D., Jiménez López, A.J., Huerta González, I., Sanz Yagüe, A., Soler López, B.

Get full text

Renal cancer treatment in Spain: An online survey by Duran, I., Sanchez Maurino, P., Garcia-Donas, J., Berthold, D. R.

“…Abstract only 397 Background: Renal cancer incidence has increased in the last decades. Many treatment options have also been developed in this period…”
Get full text